LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Average Recommendation of “Hold” by Brokerages

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has been given a consensus recommendation of “Hold” by the seven brokerages that are presently covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $105.80.

Several equities analysts have commented on LMAT shares. Barrington Research increased their target price on LeMaitre Vascular from $95.00 to $105.00 and gave the company an “outperform” rating in a research report on Thursday, February 26th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $95.00 price objective on shares of LeMaitre Vascular in a report on Monday, November 10th. Wells Fargo & Company lifted their target price on shares of LeMaitre Vascular from $87.00 to $94.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 26th. Citizens Jmp upped their price target on shares of LeMaitre Vascular from $113.00 to $118.00 and gave the company a “market outperform” rating in a research report on Thursday, February 26th. Finally, Weiss Ratings downgraded shares of LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, February 24th.

Insiders Place Their Bets

In related news, insider Trent G. Kamke sold 1,044 shares of LeMaitre Vascular stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $110.29, for a total value of $115,142.76. Following the transaction, the insider directly owned 6,677 shares of the company’s stock, valued at $736,406.33. The trade was a 13.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO George W. Lemaitre sold 150,000 shares of the stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $106.76, for a total transaction of $16,014,000.00. Following the sale, the chief executive officer directly owned 1,532,304 shares of the company’s stock, valued at $163,588,775.04. This represents a 8.92% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 215,438 shares of company stock valued at $23,062,911. 9.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On LeMaitre Vascular

Several large investors have recently modified their holdings of the company. Parkside Financial Bank & Trust raised its stake in LeMaitre Vascular by 1,913.3% during the second quarter. Parkside Financial Bank & Trust now owns 302 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 287 shares during the last quarter. Cornerstone Planning Group LLC raised its position in shares of LeMaitre Vascular by 534.0% in the 3rd quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 283 shares in the last quarter. MAI Capital Management acquired a new position in shares of LeMaitre Vascular in the 3rd quarter valued at about $38,000. First Horizon Corp bought a new stake in shares of LeMaitre Vascular during the 3rd quarter valued at about $39,000. Finally, Geneos Wealth Management Inc. boosted its position in shares of LeMaitre Vascular by 250.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 398 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

LeMaitre Vascular News Roundup

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Company announced a dividend increase (quarterly dividend raised to $0.25) and a share buyback program, a catalyst that lifted investor sentiment and helped drive the rally. Read More.
• Positive Sentiment: Analyst support has improved — at least one firm raised its price target to $118 and other shop upgrades/positive notes add buy-side conviction around the stock. Read More.
• Positive Sentiment: Technical picture is constructive after a recent “golden cross” (50‑day MA crossing above 200‑day), which can attract momentum and technical buying. Read More.
• Neutral Sentiment: Recent quarterly results beat consensus (EPS and revenue) and management set FY2026 guidance (EPS 2.81–3.01), which provides useful context for longer-term holders but is already baked into current momentum. Read More.
• Negative Sentiment: Significant insider selling was reported recently — including CEO George W. LeMaitre (150,000 shares on Feb 26 and 55,930 on Mar 2), a director sale and an officer sale — totaling roughly ~215k shares disclosed across filings; this could create short‑term selling pressure or raise governance/insider‑confidence questions for some investors. Read More.

LeMaitre Vascular Price Performance

LeMaitre Vascular stock opened at $107.85 on Wednesday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 10.95 and a current ratio of 12.89. LeMaitre Vascular has a 52 week low of $71.42 and a 52 week high of $115.33. The stock has a market capitalization of $2.46 billion, a P/E ratio of 42.97, a price-to-earnings-growth ratio of 2.01 and a beta of 0.66. The stock has a fifty day moving average of $87.95 and a 200-day moving average of $88.48.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.01. The firm had revenue of $64.45 million for the quarter, compared to analysts’ expectations of $62.98 million. LeMaitre Vascular had a return on equity of 14.72% and a net margin of 23.13%.The business’s revenue for the quarter was up 15.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.49 earnings per share. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. On average, sell-side analysts expect that LeMaitre Vascular will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 26th. Investors of record on Thursday, March 12th will be given a dividend of $0.25 per share. The ex-dividend date of this dividend is Thursday, March 12th. This represents a $1.00 annualized dividend and a yield of 0.9%. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.20. LeMaitre Vascular’s dividend payout ratio is 31.87%.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.